OncoMatch/Clinical Trials/NCT05496686
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Is NCT05496686 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for uveal melanoma.
Treatment: 4.7 microCi 225Ac-MTI-201 · 9.5 microCi of 225Ac-MTI-201 · 19 microCi of 225Ac-MTI-201 · 38 microCi of 225Ac-MTI-201 · 76 microCi of 225Ac-MTI-201 · 152 microCi of 225Ac-MTI-201 · 254 microCi of 225Ac-MTI-201 · 424 microCi of 225Ac-MTI-201 · 564 microCi of 225Ac-MTI-201 · 750 microCi of 225Ac-MTI-201 · 998 microCi of 225Ac-MTI-201 · 1327 microCi of 225Ac-MTI-201 — The primary aim of the study is to establish the maximum-tolerated dose (MTD) of 225Ac-MTI-201 in participants with metastatic uveal melanoma. The secondary aims are to describe the pharmacokinetics of 225Ac-MTI-201 and the toxic effects of 225Ac-MTI-201 in participants with metastatic uveal melanoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: any prior therapy for metastatic uveal melanoma — metastatic
Progression after at least one prior line of therapy for metastatic uveal melanoma. Liver directed therapy (e.g., hepatic arterial embolization, isolated hepatic perfusion) will count as one line of therapy.
Cannot have received: alpha-particle therapy
Prior alpha-particle therapy.
Cannot have received: external beam radiation therapy to more than 25 percent of the bone marrow
Prior external beam radiation therapy to more than 25 percent of the bone marrow.
Lab requirements
Blood counts
Leucocytes ≥ 3,000/μL; Absolute neutrophil count ≥ 1,500/μL; Platelets ≥ 100,000/μL
Kidney function
Creatinine clearance ≥ 60mL/min/1.73m^2 (Cockcroft-Gault equation, adjusted for BSA)
Liver function
AST/ALT ≤ 2.5x institutional ULN; Bilirubin ≤ 1.5x institutional ULN
Leucocytes ≥ 3,000/μL; Absolute neutrophil count ≥ 1,500/μL; Platelets ≥ 100,000/μL; AST/ALT ≤ 2.5x institutional ULN; Bilirubin ≤ 1.5x institutional ULN; Creatinine clearance ≥ 60mL/min/1.73m^2 (Cockcroft-Gault equation, adjusted for BSA)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify